27508301|t|Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy
27508301|a|Cardiovascular disease (CVD) is a leading health threat for HIV+ patients on antiretroviral therapy (ART); cardiometabolic comorbidities are key predictors of risk. Data are limited on incidence of metabolic comorbidities in HIV+ individuals initiating ART in low and middle income countries (LMICs), particularly for Hispanics. We examined incidence of diabetes and obesity in a prospective cohort of those initiating ART in the Dominican Republic. Participants ≥18 years, initiating ART <90 days prior to study enrollment, were examined for incidence of impaired fasting glucose (IFG), diabetes mellitus (DM), overweight, and obesity. Fasting plasma glucose (FPG) 100-125mg/dl defined IFG; FPG ≥126 mg/dl, diagnosis per medical record, or use of hypoglycemic medication defined DM. Overweight and obesity were BMI 25-30 and ≥30kg/m2, respectively. Dyslipidemia was total cholesterol ≥240mg/dl or use of lipid-lowering medication. Framingham risk equation was used to determine ten-year CVD risk at the end of observation. Of 153 initiating ART, 8 (6%) had DM and 23 (16%) had IFG at baseline, 6 developed DM (28/1000 person - years follow up [PYFU]) and 46 developed IFG (329/1000 PYFU). At baseline, 24 (18%) were obese and 36 (27%) were overweight, 15 became obese (69/1000 PYFU) and 22 became overweight (163/1000 PYFU). Median observation periods for the diabetes and obesity analyses were 23.5 months and 24.3 months, respectively. Increased CVD risk (≥10% 10-year Framingham risk score) was present for 13% of the cohort; 79% of the cohort had ≥1 cardiometabolic comorbidity, 48% had ≥2, and 13% had all three. In this Hispanic cohort in an LMIC, incidences of IFG / DM and overweight / obesity were similar to or higher than that found in high income countries, and cardiometabolic disorders affected three-quarters of those initiating ART. Care models incorporating cardiovascular risk reduction into HIV treatment programs are needed to prevent CVD - associated mortality in this vulnerable population.
27508301	0	9	Incidence	T081	C0021149
27508301	13	30	Diabetes Mellitus	T047	C0011849
27508301	35	42	Obesity	T047	C0028754
27508301	51	58	Overlap	T079	C1948020
27508301	62	75	Comorbidities	T078	C0009488
27508301	79	83	HIV+	T034	C0019699
27508301	84	93	Hispanics	T098	C0086409
27508301	94	104	Initiating	T169	C1704686
27508301	105	127	Antiretroviral Therapy	T061	C1963724
27508301	128	150	Cardiovascular disease	T047	C0007222
27508301	152	155	CVD	T047	C0007222
27508301	170	176	health	T078	C0018684
27508301	177	183	threat	T078	C0749385
27508301	188	192	HIV+	T034	C0019699
27508301	193	201	patients	T101	C0030705
27508301	205	227	antiretroviral therapy	T061	C1963724
27508301	229	232	ART	T061	C1963724
27508301	235	250	cardiometabolic	T047	C0025517
27508301	251	264	comorbidities	T078	C0009488
27508301	273	291	predictors of risk	T033	C0035648
27508301	293	297	Data	T078	C1511726
27508301	313	322	incidence	T081	C0021149
27508301	326	335	metabolic	T169	C0311400
27508301	336	349	comorbidities	T078	C0009488
27508301	353	357	HIV+	T034	C0019699
27508301	358	369	individuals	T098	C0237401
27508301	370	380	initiating	T169	C1704686
27508301	381	384	ART	T061	C1963724
27508301	388	391	low	T080	C0870823
27508301	396	409	middle income	T080	C0870890
27508301	410	419	countries	T083	C0454664
27508301	421	426	LMICs	T083	C0454664
27508301	429	441	particularly	T080	C0205556
27508301	446	455	Hispanics	T098	C0086409
27508301	460	468	examined	T033	C0332128
27508301	469	478	incidence	T081	C0021149
27508301	482	490	diabetes	T047	C0011847
27508301	495	502	obesity	T047	C0028754
27508301	508	526	prospective cohort	T098	C0599755
27508301	536	546	initiating	T169	C1704686
27508301	547	550	ART	T061	C1963724
27508301	558	576	Dominican Republic	T083	C0013014
27508301	578	590	Participants	T098	C0679646
27508301	595	600	years	T079	C0439234
27508301	602	612	initiating	T169	C1704686
27508301	613	616	ART	T061	C1963724
27508301	621	625	days	T079	C0439228
27508301	635	640	study	T062	C2603343
27508301	641	651	enrollment	T058	C1516879
27508301	658	666	examined	T033	C0332128
27508301	671	680	incidence	T081	C0021149
27508301	684	708	impaired fasting glucose	T033	C1272092
27508301	710	713	IFG	T033	C1272092
27508301	716	733	diabetes mellitus	T047	C0011849
27508301	735	737	DM	T047	C0011849
27508301	740	763	overweight, and obesity	T047	C1561826
27508301	765	787	Fasting plasma glucose	T059	C0583513
27508301	789	792	FPG	T059	C0583513
27508301	815	818	IFG	T033	C1272092
27508301	820	823	FPG	T059	C0583513
27508301	836	845	diagnosis	T062	C1704656
27508301	850	864	medical record	T170	C0025102
27508301	876	899	hypoglycemic medication	T121	C0020616
27508301	908	910	DM	T047	C0011849
27508301	912	934	Overweight and obesity	T047	C1561826
27508301	940	943	BMI	T201	C1305855
27508301	978	990	Dyslipidemia	T047	C0242339
27508301	995	1012	total cholesterol	T109	C0543421
27508301	1026	1032	use of	T169	C1524063
27508301	1033	1058	lipid-lowering medication	T121	C0003367
27508301	1060	1084	Framingham risk equation	T170	C3176199
27508301	1089	1093	used	T033	C1273517
27508301	1097	1106	determine	T080	C0521095
27508301	1107	1115	ten-year	T079	C0439234
27508301	1116	1119	CVD	T047	C0007222
27508301	1120	1124	risk	T058	C0086930
27508301	1132	1150	end of observation	T062	C0302523
27508301	1159	1169	initiating	T169	C1704686
27508301	1170	1173	ART	T061	C1963724
27508301	1186	1188	DM	T047	C0011849
27508301	1206	1209	IFG	T033	C1272092
27508301	1213	1221	baseline	T081	C1442488
27508301	1235	1237	DM	T047	C0011849
27508301	1247	1253	person	T098	C0027361
27508301	1256	1261	years	T079	C0439234
27508301	1262	1271	follow up	T058	C1522577
27508301	1273	1277	PYFU	T058	C1522577
27508301	1297	1300	IFG	T033	C1272092
27508301	1311	1315	PYFU	T058	C1522577
27508301	1321	1329	baseline	T081	C1442488
27508301	1345	1350	obese	T047	C0028754
27508301	1369	1379	overweight	T184	C0497406
27508301	1391	1396	obese	T047	C0028754
27508301	1406	1410	PYFU	T058	C1522577
27508301	1426	1436	overweight	T184	C0497406
27508301	1447	1451	PYFU	T058	C1522577
27508301	1454	1460	Median	T082	C2939193
27508301	1461	1472	observation	T058	C0700325
27508301	1473	1480	periods	T079	C1948053
27508301	1489	1497	diabetes	T047	C0011847
27508301	1502	1509	obesity	T047	C0028754
27508301	1510	1518	analyses	T062	C0936012
27508301	1529	1535	months	T079	C0439231
27508301	1545	1551	months	T079	C0439231
27508301	1567	1576	Increased	T081	C0205217
27508301	1577	1580	CVD	T047	C0007222
27508301	1581	1585	risk	T058	C0086930
27508301	1592	1621	10-year Framingham risk score	T033	C4086295
27508301	1627	1634	present	T033	C0150312
27508301	1650	1656	cohort	T098	C0599755
27508301	1669	1675	cohort	T098	C0599755
27508301	1683	1710	cardiometabolic comorbidity	T078	C0009488
27508301	1755	1763	Hispanic	T098	C0086409
27508301	1764	1770	cohort	T098	C0599755
27508301	1777	1781	LMIC	T083	C0454664
27508301	1783	1793	incidences	T081	C0021149
27508301	1797	1800	IFG	T033	C1272092
27508301	1803	1805	DM	T047	C0011849
27508301	1810	1820	overweight	T184	C0497406
27508301	1823	1830	obesity	T047	C0028754
27508301	1836	1843	similar	T080	C2348205
27508301	1850	1861	higher than	T080	C0205250
27508301	1867	1872	found	T033	C0150312
27508301	1876	1887	high income	T033	C0948433
27508301	1888	1897	countries	T083	C0454664
27508301	1903	1928	cardiometabolic disorders	T047	C0025517
27508301	1929	1937	affected	T169	C0392760
27508301	1962	1972	initiating	T169	C1704686
27508301	1973	1976	ART	T061	C1963724
27508301	1978	1989	Care models	T170	C0596657
27508301	2004	2023	cardiovascular risk	T047	C0850624
27508301	2024	2033	reduction	T061	C0441610
27508301	2039	2042	HIV	T047	C0019693
27508301	2043	2061	treatment programs	T058	C0679841
27508301	2066	2072	needed	T080	C0027552
27508301	2076	2083	prevent	T169	C1292733
27508301	2084	2087	CVD	T047	C0007222
27508301	2090	2100	associated	T080	C0332281
27508301	2101	2110	mortality	T081	C0205848
27508301	2119	2140	vulnerable population	T098	C0949366